{"id":63242,"date":"2026-04-15T22:02:15","date_gmt":"2026-04-15T14:02:15","guid":{"rendered":"https:\/\/flcube.com\/?p=63242"},"modified":"2026-04-15T22:02:16","modified_gmt":"2026-04-15T14:02:16","slug":"er-kim-secures-exclusive-cee-commercial-rights-for-loqtorzi-anti-pd-1-antibody-from-leo-pharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63242","title":{"rendered":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma"},"content":{"rendered":"\n<p><strong>Er-Kim<\/strong> announced on April 14, 2026, that it has signed an <strong>exclusive commercialization agreement<\/strong> with <strong>LEO Pharma A\/S<\/strong> to market <strong>LOQTORZI (toripalimab)<\/strong>, an anti-PD-1 monoclonal antibody, across <strong>11 Central and Eastern European (CEE) markets<\/strong>, marking a significant expansion of the immunotherapy&#8217;s European footprint.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-partnership-overview\">Commercial Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Commercial Partner<\/strong><\/td><td>Er-Kim<\/td><\/tr><tr><td><strong>Licensing Partner<\/strong><\/td><td>LEO Pharma A\/S<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LOQTORZI (toripalimab) \u2013 anti-PD-1 monoclonal antibody<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive commercialization rights<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>April 14, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-development-background\">Product &amp; Development Background<\/h2>\n\n\n\n<p><strong>LOQTORZI (toripalimab)<\/strong> was developed by <strong>Shanghai Junshi Biosciences Co., Ltd.<\/strong> (1877.HK\/688180.SH), a leading Chinese biopharmaceutical company specializing in innovative oncology therapeutics.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Class<\/strong>: Anti-PD-1 monoclonal antibody<\/li>\n\n\n\n<li><strong>Originator<\/strong>: Shanghai Junshi Biosciences Co., Ltd.<\/li>\n\n\n\n<li><strong>Marketing Authorization Holder (MAH)<\/strong>: TopAlliance Biosciences (wholly-owned Junshi subsidiary)<\/li>\n\n\n\n<li><strong>European Rights<\/strong>: LEO Pharma holds exclusive distribution and sales rights for EU, EEA, Switzerland, and UK (granted 2025)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-expansion\">Strategic Market Expansion<\/h2>\n\n\n\n<p>The CEE partnership represents a <strong>strategic sub-licensing arrangement<\/strong> that extends LOQTORZI&#8217;s European commercial reach beyond LEO Pharma&#8217;s core territories:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access<\/strong>: Covers 11 CEE countries representing approximately 120 million population<\/li>\n\n\n\n<li><strong>Healthcare Infrastructure<\/strong>: Diverse regulatory and reimbursement landscapes requiring specialized commercial expertise<\/li>\n\n\n\n<li><strong>Oncology Need<\/strong>: Significant unmet need for advanced immunotherapies in CEE oncology markets<\/li>\n\n\n\n<li><strong>Commercial Model<\/strong>: Er-Kim brings local market knowledge and established oncology commercial infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-analysis\">Competitive Landscape Analysis<\/h2>\n\n\n\n<p>The <strong>anti-PD-1 market<\/strong> in Central and Eastern Europe presents unique opportunities and challenges:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Penetration<\/strong>: Lower adoption rates of checkpoint inhibitors compared to Western Europe<\/li>\n\n\n\n<li><strong>Pricing Dynamics<\/strong>: More price-sensitive markets requiring value-based pricing strategies<\/li>\n\n\n\n<li><strong>Competitive Set<\/strong>: Established players include Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab)<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: LOQTORZI&#8217;s clinical data package and potential cost advantages may support market entry<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-er-kim\">For Er-Kim<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Enhancement<\/strong>: Adds premium immuno-oncology asset to existing commercial portfolio<\/li>\n\n\n\n<li><strong>Geographic Expansion<\/strong>: Strengthens presence across diverse CEE healthcare systems<\/li>\n\n\n\n<li><strong>Revenue Opportunity<\/strong>: High-value oncology product with multiple indication potential<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-leo-pharma\">For LEO Pharma<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Operational Efficiency<\/strong>: Leverages specialized partner for complex CEE markets while focusing on core territories<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Reduces commercial investment requirements in lower-margin markets<\/li>\n\n\n\n<li><strong>Revenue Stream<\/strong>: Royalty income without direct operational burden<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-junshi-biosciences\">For Junshi Biosciences<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Validation<\/strong>: Continued international partnerships validate LOQTORZI&#8217;s global competitiveness<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Multiple licensing partners reduce dependency on single markets<\/li>\n\n\n\n<li><strong>Strategic Flexibility<\/strong>: Maintains MAH status while enabling broad commercial access<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>This transaction reflects the evolving <strong>global oncology commercialization model<\/strong>, where originator companies increasingly rely on regional specialists to navigate complex local market dynamics. The CEE region represents a strategic growth frontier for immuno-oncology therapies, with improving healthcare infrastructure and increasing adoption of advanced cancer treatments.<\/p>\n\n\n\n<p>Er-Kim&#8217;s specialized focus on CEE markets positions the company to effectively execute LOQTORZI&#8217;s commercial launch, potentially establishing a template for future partnerships in emerging European markets.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial partnerships, market expansion, and revenue opportunities for LOQTORZI in Central and Eastern Europe. Actual results may differ due to risks including regulatory approvals, reimbursement negotiations, competitive dynamics, and market adoption rates in diverse CEE healthcare systems.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63243,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[819,18],"class_list":["post-63242","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-leo-pharma","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with LEO Pharma A\/S to market LOQTORZI (toripalimab), an anti-PD-1 monoclonal antibody, across 11 Central and Eastern European (CEE) markets, marking a significant expansion of the immunotherapy&#039;s European footprint.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63242\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma\" \/>\n<meta property=\"og:description\" content=\"Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with LEO Pharma A\/S to market LOQTORZI (toripalimab), an anti-PD-1 monoclonal antibody, across 11 Central and Eastern European (CEE) markets, marking a significant expansion of the immunotherapy&#039;s European footprint.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63242\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T14:02:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T14:02:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma\",\"datePublished\":\"2026-04-15T14:02:15+00:00\",\"dateModified\":\"2026-04-15T14:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242\"},\"wordCount\":512,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1505.webp\",\"keywords\":[\"LEO Pharma\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63242#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63242\",\"name\":\"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1505.webp\",\"datePublished\":\"2026-04-15T14:02:15+00:00\",\"dateModified\":\"2026-04-15T14:02:16+00:00\",\"description\":\"Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with LEO Pharma A\\\/S to market LOQTORZI (toripalimab), an anti-PD-1 monoclonal antibody, across 11 Central and Eastern European (CEE) markets, marking a significant expansion of the immunotherapy's European footprint.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63242\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63242#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma - Insight, China&#039;s Pharmaceutical Industry","description":"Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with LEO Pharma A\/S to market LOQTORZI (toripalimab), an anti-PD-1 monoclonal antibody, across 11 Central and Eastern European (CEE) markets, marking a significant expansion of the immunotherapy's European footprint.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63242","og_locale":"en_US","og_type":"article","og_title":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma","og_description":"Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with LEO Pharma A\/S to market LOQTORZI (toripalimab), an anti-PD-1 monoclonal antibody, across 11 Central and Eastern European (CEE) markets, marking a significant expansion of the immunotherapy's European footprint.","og_url":"https:\/\/flcube.com\/?p=63242","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T14:02:15+00:00","article_modified_time":"2026-04-15T14:02:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63242#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63242"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma","datePublished":"2026-04-15T14:02:15+00:00","dateModified":"2026-04-15T14:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63242"},"wordCount":512,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63242#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp","keywords":["LEO Pharma","PD-1\/L1"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63242#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63242","url":"https:\/\/flcube.com\/?p=63242","name":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63242#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63242#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp","datePublished":"2026-04-15T14:02:15+00:00","dateModified":"2026-04-15T14:02:16+00:00","description":"Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with LEO Pharma A\/S to market LOQTORZI (toripalimab), an anti-PD-1 monoclonal antibody, across 11 Central and Eastern European (CEE) markets, marking a significant expansion of the immunotherapy's European footprint.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63242#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63242"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63242#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp","width":1080,"height":608,"caption":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63242#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63242"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63242\/revisions"}],"predecessor-version":[{"id":63244,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63242\/revisions\/63244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63243"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}